Protein therapeutics (introduction to biopharmaceuticals)

Introduction to Biological and Small Molecule Drug Research and Development: Theory and Case Studies

Volumn , Issue , 2013, Pages 127-159

  Carton, Jill M ^a   Strohl, William R ^a  

^a Biologics Research   (United States)

Author keywords

(neonatal) Fc receptor (FcR(n)); (recombinant) Human growth hormone ((r)hGH); (recombinant) Polyethylene glycol (rPEG); Age related macular degeneration (AMD); Alpha glucosidase (GAA); Amyloid beta precursor (APPI); Antibody antigen binding fragment (FAb); Antibody dependent cellular cytotoxicity (ADCC); Antibody dependent cellular phagocytosis (ADCP); Biopharmaceuticals; Chinese hamster ovary (CHO); Chronic granulomatous disease (CGD); Chronic immune thrombocytopenia (ITP); Chronic myeloid leukaemia (CML); Compound annual growth rate (CAGR); Constant region (C); Cryopyrin associated periodic syndrome (CAPS); Crystallizable antibody fragment (Fc); Designed ankyrin repeat protein (DARPin); Domain antibody (dAb); Enzyme replacement therapy (ERT); Erythroid stimulating agent (ESA); Erythropoetin (EPO); Fc fusion protein (FcFP); Food and drug administration (FDA); Glucagon like peptide 1 (GLP 1); Gonadotropin releasing hormone (GnRH); Granulocyte (macrophage) colony stimulating factor (G(M) CSF); Heavy chain (HC); Hepatitis C virus (HCV); Human anti mouse antibody (HAMA); Immunoglobulin (Ig); Insulin; Insulin like growth factor 1 (IGF 1); Interferon (IFN); Light chain (LC); Mechanism of action (MOA); Monoclonal antibodies (mAb); Monoclonal antibody (mAb or Mab); Multiple sclerosis (MS); Natural killer (NK); Non antibody binding proteins (NABP); Protein therapeutics; Pure red cell aplasia (PRCA); Recombinant tissue plasminogen activator (rTPA); Single chain Fv (scFv); Tumour necrosis factor (TNF); Variable region (V); Variable region fragment or variable domain (Fv)

Indexed keywords

EID: 84903662097     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-397176-0.00004-2     Document Type: Chapter

References (31)

1. Köhler G., Milstein C. Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity. Nature 1975, 256:495-497.
2. Leader B., Baca Q.J., Golan D.E. Protein Therapeutics: A Summary and Pharmacological Classification. Nat. Rev. Drug Discovery 2008, 7:21-39.
3. Holliger P., Hudson P.J. Engineered Antibody Fragments and the Rise of Single Domains. Nat. Biotechnol. 2005, 23:1126-1136.
4. Berenson D.F., Weiss A.R., Wan Z.L., Weiss M.A. Insulin Analogs for the Treatment of Diabetes Mellitus: Therapeutic Applications of Protein Engineering. Ann. N. Y. Acad. Sci. 2011, 1243:E40-E54.
5. George P.M., Badiger R., Alazawi W., Foster G.R., Mitchell J.A. Pharmacology and Therapeutic Potential of Interferons. Pharmacol. Ther. 2012, 135:44-53.
6. Oster H.S., Neumann D., Hoffman M., Mittelman M. Erythropoietin: The Swinging Pendulum. Leuk. Res. 2012.
7. Zsebo K.M., Cohen A.M., Murdock D.C., Boone T.C., Inoue H., Chazin V.R., Hines D., Souza L.M. Recombinant Human Granulocyte Colony Stimulating Factor: Molecular and Biological Characterization. Immunobiology 1986, 172:175-184.
8. Suiter T.M. First and Next Generation Native rFVIII in the Treatment of Hemophilia A. What has been Achieved? Can Patients Be Switched Safely?. Semin. Thromb. Hemostasis 2002, 28:277-284.
9. Morris J.L. Velaglucerase Alfa for the Management of Type 1 Gaucher Disease. Clin. Ther. 2012, 34:259-271.
10. Latham P.W. Therapeutic Peptides Revisited. Nat. Biotechnol. 1999, 17:755-757.
11. Morrison S.L., Johnson M.J., Herzenberg L.A., Oi V.T. Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains. Proc. Natl. Acad. Sci. U.S.A. 1984, 81:6851-6855.
12. Jiang X.R., Song A., Bergelson S., Arroll T., Parekh B., May K., Chung S., Strouse R., Mire-Sluis A., Schenerman M. Advances in the Assessment and Control of the Effector Functions of Therapeutic Antibodies. Nat. Rev. Drug Discovery 2011, 10:101-111.
13. Reddy M.P., Kinney C.A., Chaikin M.A., Payne A., Fishman-Lobell J., Tsui P., Dal Monte P.R., Doyle M.L., Brigham-Burke M.R., Anderson D., Reff M., Newman R., Hanna N., Sweet R.W., Truneh A. Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4. J. Immunol. 2000, 164:1925-1933.
14. Huang C. Receptor-Fc Fusion Therapeutics, Traps, and MIMETIBODY Technology. Curr. Opin. Biotechnol. 2009, 20:692-699.
15. Loffler A., Kufer P., Lutterbuse R., Zettl F., Daniel P.T., Schwenkenbecher J.M., Riethmuller G., Dorken B., Bargou R.C. A Recombinant Bispecific Single-Chain Antibody, CD19×CD3, Induces Rapid and High Lymphoma-Directed Cytotoxicity By Unstimulated T Lymphocytes. Blood 2000, 95:2098-2103.
16. Wolfson W. Ablynx Makes Nanobodies from Llama Bodies. Chem. Biol. 2006, 13:1243-1244.
17. Steiner D., Forrer P., Pluckthun A. Efficient Selection of DARPins With Sub-Nanomolar Affinities Using SRP Phage Display. J. Mol. Biol. 2008, 382:1211-1227.
18. Buttel I.C., Chamberlain P., Chowers Y., Ehmann F., Greinacher A., Jefferis R., Kramer D., Kropshofer H., Lloyd P., Lubiniecki A., Krause R., Mire-Sluis A., Platts-Mills T., Ragheb J.A., Reipert B.M., Schellekens H., Seitz R., Stas P., Subramanyam M., Thorpe R., Trouvin J.H., Weise M., Windisch J., Schneider C.K. Taking Immunogenicity Assessment of Therapeutic Proteins to the Next Level. Biologicals 2011, 39:100-109.
19. Lubiniecki A., Volkin D.B., Federici M., Bond M.D., Nedved M.L., Hendricks L., Mehndiratta P., Bruner M., Burman S., Dalmonte P., Kline J., Ni A., Panek M.E., Pikounis B., Powers G., Vafa O., Siegel R. Comparability Assessments of Process and Product Changes Made During Development of Two Different Monoclonal Antibodies. Biologicals 2011, 39:9-22.
20. Eppstein D.A., Longenecker J.P. Alternative Delivery Systems for Peptides and Proteins as Drugs. Crit. Rev. Ther. Drug Carrier Syst. 1988, 5:99-139.
21. An Z. Therapeutic Monoclonal Antibodies: From Bench to Clinic 2009, John Wiley and Sons, Inc, Hoboken, NJ.
22. Strohl W.R., Strohl L.M. Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharma Industry 2012, Woodhead Publishing, Cambridge.
23. La Merie Business Intelligence, Top 30 Biologics 2011. R&D Pipeline News [1/2012], 2012, 1-30.
24. Aggarwal S. What's Fueling the Biotech Engine-2010 to 2011. Nat. Biotechnol. 2011, 29(12):1083-1089.
25. Binz H.K., Amstutz P., Pluckthun A. Engineering Novel Binding Proteins from Nonimmunoglobulin Domains. Nat. Biotechnol. 2005, 23(10):1257-1268.
26. Birch J.R., Racher A.J. Antibody Production. Adv. Drug Delivery Rev. 2006, 58(5-6):671-685.
27. Carter P.J. Introduction to Current and Future Protein Therapeutics: A Protein Engineering Perspective. Exp. Cell. Res. 2011, 317(9):1261-1269.
28. Dingermann T. Recombinant Therapeutic Proteins: Production Platforms and Challenges. J. Biotechnol. 2008, 3(1):90-97.
29. Sato A.K., Viswanathan M., Kent R.B., Wood C.R. Therapeutic Peptides: Technological Advances Driving Peptides into Development. Curr. Opin. Biotechnol. 2006, 17(6):638-642.
30. Skerra A. Alternative Non-antibody Scaffolds for Molecular Recognition. Curr. Opin. Biotechnol. 2007, 18(4):295-304.
31. Strohl W.R., Knight D.M. Discovery and Development of Biopharmaceuticals: Current Issues. Curr. Opin. Biotechnol. 2009, 20(6):668-672.